These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 12072950

  • 1. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G, Roig C, Miró E, Navarro F, Mirelis B.
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract] [Full Text] [Related]

  • 2. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP, Mingoia M, Varaldo PE.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [Abstract] [Full Text] [Related]

  • 3. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
    Montanari MP, Ferrante L, Tili E, Cochetti I, Rossi V, Varaldo PE.
    J Chemother; 2005 Apr; 17(2):138-42. PubMed ID: 15920898
    [Abstract] [Full Text] [Related]

  • 4. Prulifloxacin.
    Keam SJ, Perry CM.
    Drugs; 2004 Apr; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [Abstract] [Full Text] [Related]

  • 5. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M, Hara T, Watabe H, Nishino T.
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [Abstract] [Full Text] [Related]

  • 6. Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116).
    Morita S, Otsubo K, Matsubara J, Ohtani T, Kawano Y, Ohmori K, Ohguro K, Uchida M.
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2246-52. PubMed ID: 8582026
    [Abstract] [Full Text] [Related]

  • 7. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S, Ianniello F, Leone S, Esposito S.
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [Abstract] [Full Text] [Related]

  • 8. Postantibiotic effects of E-4868 and OPC-17116.
    Sanford MD, Jones RN.
    J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y, Ozaki M, Matsuda M, Honmura T, Nishimura I, Yamaguchi R, Adachi T, Okawa Y, Nishino T.
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL, Fuchs PC.
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M, Coll R, Esteve M, Parés J, Xicota MA.
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract] [Full Text] [Related]

  • 12. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M, Kuga A, Kaieda S, Hosaka M, Kitasato H, Sato Y, Okamoto R, Eda T, Hoshino K, Seto I.
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [Abstract] [Full Text] [Related]

  • 13. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
    Padeĭskaia EN, Iakovlev VP.
    Antibiot Khimioter; 1998 Sep; 43(2):30-9. PubMed ID: 9551171
    [No Abstract] [Full Text] [Related]

  • 14. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG, Delidou K, Grigoriadou A, Salpigides G, Pangalis A.
    Drugs; 1995 Sep; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract] [Full Text] [Related]

  • 15. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G, Rossi V, Salvatori E, Mirelis B.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ, Panchal S, Norte V.
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic characteristics of prulifloxacin.
    Matera MG.
    Pulm Pharmacol Ther; 2006 Jun; 19 Suppl 1():20-9. PubMed ID: 16360331
    [Abstract] [Full Text] [Related]

  • 19. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H, Kawazoe K, Izumi K, Ito K, Tamaya T.
    Drugs; 1995 Jun; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract] [Full Text] [Related]

  • 20. In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative.
    Ozaki M, Tomii Y, Matsuda M, Segawa J, Kitano M, Kise M, Nishino T.
    Chemotherapy; 1998 Jun; 44(1):21-30. PubMed ID: 9444405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.